

桃園長庚紀念醫院

抗生素敏感性試驗

2021年報

JAN. ~DEC.

檢驗醫學部 微生物組

感染管制委員會

製表

GRAM (-) BACILLI

JAN. ~ DEC., 2021

| ANTIBIOTICS BACTERIA | TOTAL (no.)* | PERCENT OF SUSCEPTIBILITY** | | | | | | | | | | | | | | | | | | |
|-------------------------------|--------------|-----------------------------|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|
| | | AMC | AN | CAZ | CIP | CL | CPS | CRO | CXM | CZ | DOR | ETP | FEP | GM | IPM | LVX | MEM | SAM | SXT | TZP |
| Citrobacter koseri | 44 | 87 | 95 | 93 | 89 | - | 91 | 84 | 82 | 80 | - | 93 | - | 98 | - | 86 | - | 93 | 87 | 89 |
| Escherichia coli | 709 | 73 | 100 | 81 | 50 | - | 98 | 73 | 70 | 38 | - | 100 | - | 80 | - | 59 | - | 72 | 59 | 97 |
| Klebsiella pneumoniae | 175 | 59 | 95 | 77 | 47 | - | 84 | 79 | 64 | 51 | - | 86 | - | 74 | - | 65 | - | 67 | 54 | 73 |
| Proteus mirabilis | 93 | 82 | 96 | 96 | 72 | - | 98 | 91 | 92 | 17 | - | 100 | - | 83 | - | 80 | - | 76 | 57 | 100 |
| Pseudomonas aeruginosa | 143 | - | 99 | 91 | 76 | 100 | 87 | - | - | - | 92 | - | 93 | 95 | 82 | 69 | 87 | - | - | 90 |

AMC=amoxicillin/clavulanic acid; AM=ampicillin; AN=amikacin; CAZ=ceftazidime; CIP=ciprofloxacin; CL=colistin; CLR=clarithromycin; CPS=cefoperazone-sulbactam; CRO=ceftriaxone; CXM=cefuroxime; CZ=cefazolin; DOR=doripemun; ETP=ertapenem; FEP=cefepime; GM=gentamicin; IPM=imipenem; LVX=levofloxacin; MEM=meropenem; SAM=ampicillin-sulbactam; SXT=sulfamethoxazole-trimethoprim; TZP=piperacillin-tazobactam; - =not tested or not available

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

**本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用; CR或MDR菌株均已併入原菌株結果一起檢視.

GRAM (+) BACTERIA

JAN. ~ DEC., 2021

| ANTIBIOTICS BACTERIA | TOTAL (no.)* | PERCENT OF SUSCEPTIBILITY** | | | | | | | | | | | | | | |
|----------------------------|--------------|-----------------------------|----|-----|----|----|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|
| | | AM | CC | CRO | E | FA | HGM | LVX | LZD | MXF | OX | P | SXT | TEC | TGC | VA |
| Beta strep. group B | 67 | 100 | 47 | 100 | 47 | - | - | - | - | - | - | 100 | - | 100 | - | 100 |
| Enterococcus faecalis | 95 | 100 | - | - | - | - | 55 | - | - | - | - | 96 | - | 100 | - | 100 |
| Staphylococcus aureus | 211 | - | 70 | - | 43 | 93 | - | - | 100 | - | 48 | 5 | 96 | 100 | 100 | 100 |
| Staphylococcus epidermidis | 100 | - | 57 | - | 51 | - | - | - | - | - | 39 | 10 | 77 | 100 | - | 100 |
| Streptococcus pneumoniae | 4 | - | - | # | - | - | - | 100 | - | 100 | - | # | - | - | - | 100 |

AM=ampicillin; CC=clindamycin; CRO=ceftriaxone; E=erythromycin; FA=fusidic acid; HGM= high level gentamicin; LVX=levofloxacin; LZD=linezolid; MXF=moxifloxacin; OX=oxacillin; P=penicillin-G; SXT = sulfamethoxazole-trimethoprim; TEC=teicoplanin; TGC=tigecyclin; VA=vancomycin;

- = not tested or not available

Streptococcus pneumoniae對penicillin與ceftriaxone的藥敏結果綜合整理於最後

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上;

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

**本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用.

Anaerobes

JAN. ~ DEC., 2021

| ANTIBIOTICS BACTERIA@ | TOTAL (no.)* | PERCENT OF SUSCEPTIBILITY ** | | | | |
|--------------------------|--------------|------------------------------|-----|-----|-----|-----|
| | | CC | MET | P | PIP | SAM |
| Finegoldia magna | 36 | 50 | 100 | 100 | 100 | 100 |

CC=clindamycin; MET=metronidazole; P=penicillin-G; PIP=piperacillin; SAM = ampicillin-sulbactam

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

@本年度新上榜的細菌名稱以紅字標示;

*本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得
第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用

Streptococcus pneumoniae

JAN. ~ DEC., 2021

| 抗生素 種類 | 檢體別 | 判讀標準 | 結果分類 | 全院 | | |
|--------------|--------------------------------|--------------------------|-------------------|-------|-----|-------|
| | | | (濃度範圍, mg/L) | 總菌株數* | 菌株數 | %** |
| Penicillin-G | CSF | meningitis 標準 | S (≤ 0.06) | 0 | 0 | 0.0 |
| | | | - | | - | - |
| | | | R (≥ 0.12) | | 0 | 0.0 |
| | Other invasive specimens | meningitis 標準 | S (≤ 0.06) | 1 | 0 | 0.0 |
| | | | - | | - | - |
| | | | R (≥ 0.12) | | 1 | 100.0 |
| | | non- meningitis 標準 | S (≤ 2) | | 1 | 100.0 |
| | | | I (4) | | 0 | 0.0 |
| | | | R (≥ 8) | | 0 | 0.0 |
| | Non- invasive specimens | non- meningitis 標準 | S (≤ 2) | 3 | 3 | 100.0 |
| | | | I (4) | | 0 | 0.0 |
| | | | R (≥ 8) | | 0 | 0.0 |
| Ceftriaxone | CSF | meningitis 標準 | S (≤ 0.5) | 0 | 0 | 0.0 |
| | | | I (1) | | 0 | 0.0 |
| | | | R (≥ 2) | | 0 | 0.0 |
| | Other invasive specimens | meningitis 標準 | S (≤ 0.5) | 1 | 1 | 100.0 |
| | | | I (1) | | 0 | 0.0 |
| | | | R (≥ 2) | | 0 | 0.0 |
| | | non- meningitis 標準 | S (≤ 1) | | 1 | 100.0 |
| | | | I (2) | | 0 | 0.0 |
| | | | R (≥ 4) | | 0 | 0.0 |
| | Non- invasive specimens | non- meningitis 標準 | S (≤ 1) | 3 | 3 | 100.0 |
| | | | I (2) | | 0 | 0.0 |
| | | | R (≥ 4) | | 0 | 0.0 |

*紅字代表細菌數目較去年多10%以上；藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上；藍字代表較去年高10以上

GRAM (-) BACILLI - nosocomial isolates only
NOSOCOMIAL ISOLATES ONLY
201901-202112

| ANTIBIOTICS BACTERIA | TOTAL (no.) | PERCENT OF SUSCEPTIBILITY** | | | | | | | | | | | | | | | | |
|---------------------------------|-------------|-----------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | | AMC | AN | CAZ | CIP | CPS | CRO | CXM | CZ | DOR | ETP | FEP | GM | IPM | LVX | MEM | SXT | TZP |
| Escherichia coli & | 89 | 68 | 99 | 75 | 32 | 76 | 48 | 46 | 32 | - | 100 | - | 72 | - | 42 | - | 54 | 95 |
| Klebsiella pneumoniae && | 38 | 48 | 89 | 78 | 47 | 82 | 67 | 52 | 42 | - | 89 | - | 64 | - | 61 | - | 48 | 72 |
| Pseudomonas aeruginosa | 20 | - | 100 | 90 | 80 | 80 | - | - | - | 95 | - | 95 | 100 | 80 | 75 | 95 | - | 85 |

AMC=amoxicillin/clavulanic acid; AN=amikacin; CAZ=ceftazidime; CIP=ciprofloxacin; CPS=cefoperazone-sulbactam; CRO=ceftriaxone; CXM=cefuroxime; CZ=cefazolin; DOR=doripemun; ETP=ertapenem; FEP=cefepime; GM=gentamicin; IPM=imipenem; LVX=levofloxacin; MEM=meropenem; SXT=sulfamethoxazole-trimethoprim; TZP=piperacillin-tazobactam; - =not tested or not available

&上表中所列數字, 已包含CR及菌株 1 株(1%)

&&上表中所列數字, 已包含CR及MDR菌株 4 株(11%)

**GRAM (+) BACTERIA
NOSOCOMIAL ISOLATES ONLY
201901-202112**

| ANTIBIOTICS BACTERIA | TOTAL (no.) | PERCENT OF SUSCEPTIBILITY** | | | | | | | | | | | |
|--|-------------|-----------------------------|-----|----|----|-----|-----|----|-----|-----|-----|-----|-----|
| | | AM | CC | E | FA | HGM | LZD | OX | P | SXT | TEC | TGC | VA |
| Enterococcus faecalis | 11 | 100 | - | - | - | 45 | - | - | 100 | - | 100 | - | 100 |
| Staphylococcus aureus ^{&} | 20 | - | 100 | 78 | 95 | - | 90 | 60 | 0 | 100 | 100 | 100 | 100 |

AM=ampicillin; CC=clindamycin; E=erythromycin; FA=fusidic acid; HGM= high level gentamicin; LZD=linezolid;
OX=oxacillin; P=penicillin-G; SXT = sulfamethoxazole-trimethoprim; TEC=teicoplanin; TGC=tigecyclin; VA=vancomycin;

- = not tested or not available

& S. aureus含MRSA 8株 (40%)